CoChat
Sign Up
Cited by 204Osteoarthritis Treatment and MechanismsRheumatoid Arthritis Research and TherapiesProteoglycans and glycosaminoglycans research

Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis

Open access
Tseng, Susan, Reddi, A. Hari, Di Cesare, Paul E.·2009·Biomarker Insights
DOI 10.4137/bmi.s645PMC PMC2716683
Open this paper in CoChat — free accountOpen PDF

Abstract

Arthritis is a chronic disease with a significant impact on the population. It damages the cartilage, synovium, and bone of the joints causing pain, impairment, and disability in patients. Current methods for diagnosis of and monitoring the disease are only able to detect clinical manifestations of arthritis late in the process. However, with the recent onset of successful treatments for rheumatoid arthritis and osteoarthritis, it becomes important to identify prognostic factors that can predict the evolution of arthritis. This is especially critical in the early phases of disease so that these treatments can be started as soon as possible to slow down progression of the disease. A valuable approach to monitor arthritis would be by measuring biological markers of cartilage degradation and repair to reflect variations in joint remodeling. One such potential biological marker of arthritis is cartilage oligomeric matrix protein (COMP). In various studies, COMP has shown promise as a diagnostic and prognostic indicator and as a marker of the disease severity and the effect of treatment. This review highlights the progress in the utilization of COMP as a biomarker of arthritis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4137/bmi.s645

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • COMP correlates with age, BMI, pain, and IL-1β, shows gender differences, and has negative associations with disease duration.

    “correlates with age, BMI, pain, and IL-1β, gender differences, and has negative associations with disease duration [27].”

    From Biomarker-Guided Imaging and AI-Augmented Diagnosis of Degenerative Joint Disease (2025) · cites this paper as [27]

    The Biological Variations of COMP section (page unavailable) reports associations of serum COMP with age and BMI, a lower-limb pain score in OA patients, and gender differences. Our copy does not report a correlation with IL-1β or a negative association with disease duration; searches for those terms found no supporting passage. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • COMP is released into blood during cartilage turnover and displays increased levels in OA patients.

    “Released into blood during cartilage turnover, it displays increased levels in OA patients”

    From Biomarker-Guided Imaging and AI-Augmented Diagnosis of Degenerative Joint Disease (2025) · cites this paper as [27]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 89

  1. [1]Hinton R Moody RL Davis AW Thomas SF Osteoarthritis: diagnosis and therapeutic considerations Am Fam Physician 2002 65 841 8 11898956
  2. [2]Rindfleisch JA Muller D Diagnosis and management of rheumatoid arthritis Am Fam Physician 2005 72 1037 47 16190501
  3. [3]Manek NJ Lane NE Osteoarthritis: current concepts in diagnosis and management Am Fam Physician 2000 61 1795 804 10750883
  4. [4]Jacobson JA Girish G Jiang Y Resnick D Radiographic evaluation of arthritis: inflammatory conditions Radiology 2008a 248 378 89 18641245
  5. [5]Jacobson JA Girish G Jiang Y Sabb BJ Radiographic evaluation of arthritis: degenerative joint disease and variations Radiology 2008b 248 737 47 18710973
  6. [6]Harris ED Jr Rheumatoid arthritis. Pathophysiology and implications for therapy N Engl J Med 1990 322 1277 89 2271017
  7. [7]Martin JA Buckwalter JA The role of chondrocyte senescence in the pathogenesis of osteoarthritis and in limiting cartilage repair J Bone Joint Surg Am 2003 85 A Suppl 2 106 10 12721352
  8. [8]Buckwalter JA Mankin HJ Grodzinsky AJ Articular cartilage and osteoarthritis Instr Course Lect 2005 54 465 80 15952258
  9. [9]Martin JA Ellerbroek SM Buckwalter JA Age-related decline in chondrocyte response to insulin-like growth factor-I: the role of growth factor binding proteins J Orthop Res 1997 15 491 8 9379257
  10. [10]Hayashi M Muneta T Ju YJ Mochizuki T Sekiya I Weekly intraarticular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression Arthritis Res Ther 2008 10 R118 18826579 PMC2592805
  11. [11]Badlani N Inoue A Healey R Coutts R Amiel D The protective effect of OP-1 on articular cartilage in the development of osteoarthritis Osteoarthritis Cartilage 2008 16 600 6 17977753
  12. [12]Lane SK Gravel JW Jr Clinical utility of common serum rheumatologic tests Am Fam Physician 2002 65 1073 80 11925083
  13. [13]Kushner I Rzewnicki D Samols D What does minor elevation of C-reactive protein signify? Am J Med 2006 119 166 e17 28 16443421
  14. [14]van Leeuwen MA Van rijswijk MH Van der heijde DM The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease Br J Rheumatol 1993 32 Suppl 3 9 13 8508266
  15. [15]Sturmer T Brenner H Koenig W Gunther KP Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein Ann Rheum Dis 2004 63 200 5 14722211 PMC1754873
  16. [16]Anzilotti C Merlini G Pratesi F Tommasi C Chimenti D Migliorini P Antibodies to viral citrullinated peptide in rheumatoid arthritis J Rheumatol 2006 33 647 51 16511941
  17. [17]Caspi D Anouk M Golan I Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis Arthritis Rheum 2006 55 53 6 16463412
  18. [18]Gottenberg JE Mignot S Nicaise-rolland P Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren’s syndrome Ann Rheum Dis 2005 64 114 7 15231509 PMC1755190
  19. [19]Korendowych E Owen P Ravindran J Carmichael C Mchugh N The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis Rheumatology (Oxford) 2005 44 1056 60 15901902
  20. [20]Low JM Chauhan AK Kietz DA Daud U Pepmueller PH Moore TL Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis J Rheumatol 2004 31 1829 33 15338508
  21. [21]Russell AS Devani A Maksymowych WP The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis J Rheumatol 2006 33 1240 2 16724377
  22. [22]Sene D Ghillani-dalbin P Limal N Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren’s syndrome Ann Rheum Dis 2006 65 394 7 16474032 PMC1798048
  23. [23]Bizzaro N Mazzanti G Tonutti E Villalta D Tozzoli R Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis Clin Chem 2001 47 1089 93 11375296
  24. [24]Lopez-hoyos M Ruiz de alegria C Blanco R Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica Rheumatology (Oxford) 2004 43 655 7 14970400
  25. [25]Shmerling RH Delbanco TL The rheumatoid factor: an analysis of clinical utility Am J Med 1991 91 528 34 1951415
  26. [26]Shmerling RH Delbanco TL How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value Arch Intern Med 1992 152 2417 20 1456851
  27. [27]Matsui T Shimada K Ozawa N Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis J Rheumatol 2006 33 2390 7 16924694
  28. [28]Elkayam O Segal R Lidgi M Caspi D Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis Ann Rheum Dis 2006 65 1110 2 16361276 PMC1798246
  29. [29]Pelletier JP Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis Osteoarthritis Cartilage 2004 12 Suppl A S63 8 14698646
  30. [30]Donahue KE Gartlehner G Jonas DE Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis Ann Intern Med 2008 148 124 34 18025440
  31. [31]Heinegard D Inerot S Wieslander J Lindblad G A method for the quantification of cartilage proteoglycan structures liberated to the synovial fluid during developing degenerative joint disease Scand J Clin Lab Invest 1985 45 421 7 4035279
  32. [32]Saxne T Heinegard D Wollheim FA Pettersson H Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis Lancet 1985 2 127 8 2862321
  33. [33]Ostendorf RH Van de stadt RJ Van kampen GP Intermittent loading induces the expression of 3–B–3(–) epitope in cultured bovine articular cartilage J Rheumatol 1994 21 287 92 7514226
  34. [34]Carlson CS Loeser RF Johnstone B Tulli HM Dobson DB Caterson B Osteoarthritis in cynomolgus macaques. II. Detection of modulated proteoglycan epitopes in cartilage and synovial fluid J Orthop Res 1995 13 399 409 7541454
  35. [35]Sweet MB Coelho A Schnitzler CM Serum keratan sulfate levels in osteoarthritis patients Arthritis Rheum 1988 31 648 52 2967706
  36. [36]Seibel MJ Duncan A Robins SP Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases J Rheumatol 1989 16 964 70 2769668
  37. [37]Pelletier JP Martel-pelletier J Howell DS Ghandurmnaymneh L Enis JE Woessner JF Jr Collagenase and collagenolytic activity in human osteoarthritic cartilage Arthritis Rheum 1983 26 63 8 6297508
  38. [38]Walakovits LA Moore VL Bhardwaj N Gallick GS Lark MW Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury Arthritis Rheum 1992 35 35 42 1370619
  39. [39]Flood S Parri R Williams A Duance V Mason D Modulation of interleukin-6 and matrix metalloproteinase 2 expression in human fibroblast-like synoviocytes by functional ionotropic glutamate receptors Arthritis Rheum 2007 56 2523 34 17665433
  40. [40]Giannelli G Erriquez R Iannone F Marinosci F Lapadula G Antonaci S MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis Clin Exp Rheumatol 2004 22 335 8 15144129
  41. [41]Hulejova H Baresova V Klezl Z Polanska M Adam M Senolt L Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone Cytokine 2007 38 151 6 17689092
  42. [42]Rioja I Hughes FJ Sharp CH Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor Arthritis Rheum 2008 58 2257 67 18668547
  43. [43]Garnero P Rousseau JC Delmas PD Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases Arthritis Rheum 2000 43 953 68 10817547
  44. [44]Hedbom E Antonsson P Hjerpe A Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage J Biol Chem 1992 267 6132 6 1556121
  45. [45]Oldberg A Antonsson P Lindblom K Heinegard D COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins J Biol Chem 1992 267 22346 50 1429587
  46. [46]Halasz K Kassner A Morgelin M Heinegard D COMP acts as a catalyst in collagen fibrillogenesis J Biol Chem 2007 282 31166 73 17716974
  47. [47]Chen FH Herndon ME Patel N Hecht JT Tuan RS Lawler J Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan J Biol Chem 2007 282 24591 8 17588949 PMC2905148
  48. [48]Mann HH Ozbek S Engel J Paulsson M Wagener R Interactions between the cartilage oligomeric matrix protein and matrilins. Implications for matrix assembly and the pathogenesis of chondrodysplasias J Biol Chem 2004 279 25294 8 15075323
  49. [49]Johnson A Smith R Saxne T Hickery M Heinegard D Fibronectin fragments cause release and degradation of collagen-binding molecules from equine explant cultures Osteoarthritis Cartilage 2004 12 149 59 14723874
  50. [50]Dicesare P Hauser N Lehman D Pasumarti S Paulsson M Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon FEBS Lett 1994 354 237 40 7957930
  51. [51]Di cesare PE Fang C Leslie MP Tulli H Perris R Carlson CS Expression of cartilage oligomeric matrix protein (COMP) by embryonic and adult osteoblasts J Orthop Res 2000 18 713 20 11117291
  52. [52]Saxne T Heinegard D Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood Br J Rheumatol 1992 31 583 91 1381980
  53. [53]Arai K Misumi K Carter SD Shinbara S Fujiki M Sakamoto H Analysis of cartilage oligomeric matrix protein (COMP) degradation and synthesis in equine joint disease Equine Vet J 2005 37 31 6 15651731
  54. [54]Vilim V Voburka Z Vytasek R Monoclonal antibodies to human cartilage oligomeric matrix protein: epitope mapping and characterization of sandwich ELISA Clin Chim Acta 2003 328 59 69 12559599
  55. [55]Misumi K Vilim V Clegg PD Thompson CC Carter SD Measurement of cartilage oligomeric matrix protein (COMP) in normal and diseased equine synovial fluids Osteoarthritis Cartilage 2001 9 119 27 11237659
  56. [56]Neidhart M Hauser N Paulsson M Dicesare PE Michel BA Hauselmann HJ Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation Br J Rheumatol 1997 36 1151 60 9402858
  57. [57]Dicesare PE Morgelin M Carlson CS Pasumarti S Paulsson M Cartilage oligomeric matrix protein: isolation and characterization from human articular cartilage J Orthop Res 1995 13 422 8 7602403
  58. [58]Clark AG Jordan JM Vilim V Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project Arthritis Rheum 1999 42 2356 64 10555031
  59. [59]Conrozier T Saxne T Fan CS Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study Ann Rheum Dis 1998 57 527 32 9849311 PMC1752738
  60. [60]Petersson IF Boegard T Dahlstrom J Svensson B Heinegard D Saxne T Bone scan and serum markers of bone and cartilage in patients with knee pain and osteoarthritis Osteoarthritis Cartilage 1998a 6 33 9 9616437
  61. [61]Bleasel JF Poole AR Heinegard D Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation Arthritis Rheum 1999 42 39 45 9920012
  62. [62]Kellgren JH Lawrence JS Radiological assessment of osteoarthrosis Ann Rheum Dis 1957 16 494 502 13498604 PMC1006995
  63. [63]Vingsbolundberg C Saxne T Olsson H Holmdahl R Increased serum levels of cartilage oligomeric matrix protein in chronic erosive arthritis in rats Arthritis Rheum 1998 41 544 50 9506583 PMC7159671
  64. [64]Larsson E Erlandsson harris H Larsson A Mansson B Saxne T Klareskog L Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP Rheumatology (Oxford) 2004 43 428 34 15024132
  65. [65]Vilim V Vytasek R Olejarova M Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis Osteoarthritis Cartilage 2001 9 612 8 11597173
  66. [66]Skoumal M Haberhauer G Feyertag J Kittl EM Bauer K Dunky A Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud’s syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjogren’s syndrome Arthritis Res Ther 2004 6 73 4 15059267 PMC400441
  67. [67]Nikolaisen C Rekvig OP Nossent HC Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis Scand J Rheumatol 2007 36 97 100 17476614
  68. [68]Forslind K Eberhardt K Jonsson A Saxne T Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis Br J Rheumatol 1992 31 593 8 1525624
  69. [69]Mansson B Carey D Alini M Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism J Clin Invest 1995 95 1071 7 7533784 PMC441442
  70. [70]Wollheim FA Eberhardt KB Johnson U Saxne T HLADRB1* typing and cartilage oligomeric matrix protein (COMP) as predictors of joint destruction in recent-onset rheumatoid arthritis Br J Rheumatol 1997 36 847 9 9291852
  71. [71]Sharif M Saxne T Shepstone L Relationship between serum cartilage oligomeric matrix protein levels and disease progression in osteoarthritis of the knee joint Br J Rheumatol 34 306 10 7788143
  72. [72]Petersson IF Boegard T Svensson B Heinegard D Saxne T Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint Br J Rheumatol 1998b 37 46 50 9487250
  73. [73]Vilim V Olejarova M Machacek S Gatterova J Kraus VB Pavelka K Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis Osteoarthritis Cartilage 2002 10 707 13 12202123
  74. [74]Sharif M Kirwan JR Elson CJ Granell R Clarke S Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years Arthritis Rheum 2004 50 2479 88 15334461
  75. [75]Kuhne SA Neidhart M Everson MP Persistent high serum levels of cartilage oligomeric matrix protein in a subgroup of patients with traumatic knee injury Rheumatol Int 1998 18 21 5 9672995
  76. [76]Dragomir AD Kraus VB Renner JB Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology Osteoarthritis Cartilage 2002 10 687 91 12202121
  77. [77]Crnkic M Mansson B Larsson L Geborek P Heinegard D Saxne T Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept Arthritis Res Ther 2003 5 R181 5 12823852 PMC165057
  78. [78]Morozzi G Fabbroni M Bellisai F Cucini S Simpatico A Galeazzi M Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR 70 response to adalimumab therapy in rheumatoid arthritis Clin Rheumatol 2007a 26 1335 8 17285224
  79. [79]Morozzi G Fabbroni M Bellisai F Pucci G Galeazzi M Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/ or the therapeutic efficacy of treatments Ann NY Acad Sci 2007b 1108 398 407 17894003
  80. [80]Felson DT Anderson JJ Boers M American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum 1995 38 727 35 7779114
  81. [81]Bruyere O Collette JH Ethgen O Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis J Rheumatol 2003a 30 1043 50 12734904
  82. [82]Bruyere O Honore A Ethgen O Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate Osteoarthritis Cartilage 2003b 11 1 5 12505481
  83. [83]Forsblad d’elia H Christgau S Mattsson LA Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] Arthritis Res Ther 2004 6 R457 68 15380045 PMC546286
  84. [84]Weitoft T Larsson A Saxne T Ronnblom L Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis Ann Rheum Dis 2005 64 1750 3 15843449 PMC1755303
  85. [85]Skoumal M Haberhauer G Feyertag J Kittl EM Bauer K Dunky A Serumlevels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment Rheumatol Int 2006 26 1001 4 16485108
  86. [86]Jordan JM Luta G Stabler T Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project Arthritis Rheum 2003 48 675 81 12632420
  87. [87]Wislowska M Jablonska B Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis Clin Rheumatol 2005 24 278 84 15940561
  88. [88]Andersson ML Thorstensson CA Roos EM Petersson IF Heinegard D Saxne T Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis BMC Musculoskelet Disord 2006b 7 98 17156423 PMC1712338
  89. [89]Andersson ML Petersson IF Karlsson KE Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis Ann Rheum Dis 2006a 65 1490 4 16707535 PMC1798358

Cited by

Sorted by citations

Authors
Tseng, S., Reddi, A. H., & Di Cesare, P. E.
Affiliations
  • University of California Davis Medical Center (US)
  • Department of Orthopaedic Surgery, UC Davis Medical Center, Sacramento, California, 95817, U.S.A.
ORCID
Reddi, A. Hari
Venue
Biomarker Insights
Publisher
SAGE Publications
Published
2009-01
Volume
4
Pages
BMI.S645
ISSN
1177-2719 (ISSN-L)
DOI
10.4137/bmi.s645
PMC
PMC2716683
OpenAlex
W1523661940
Cited by
204
References
0
Citations by year
2026: 14 · 2025: 11 · 2024: 11 · 2023: 15 · 2022: 22 · 2021: 18 · 2020: 10 · 2019: 8 · 2018: 10 · 2017: 15 · 2016: 8 · 2015: 16 · 2014: 12 · 2013: 11 · 2012: 8
FWCI
5.44
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomarker Insights (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
Keywords
cartilage oligomeric matrix protein, COMP, arthritis, biomarkers, rheumatoid arthritis, osteoarthritis, cartilage degeneration, cartilage repair, disease severity, treatment response monitoring, prognosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review